skip to main content

Rogel Cancer Center at AACR Annual Meeting

Date Visible: 
03/25/2024 - 11:15am

Media contact: Anna Megdell, 734-764-2220 |  Patients may contact Cancer AnswerLine™ 800-865-1125

Rogel Cancer Center faculty and trainees will lead nearly 70 presentations, posters and moderated sessions at the American Association for Cancer Research annual meeting.

AACR 2024 annual meeting logo
Courtesy AACR

Check out the list of U-M presenters to support your colleagues. Connect with researchers on X/Twitter using #AACR24. Be sure to tag @UMRogelCancer.

Presenter information is sometimes incomplete. If your session is missing, please email the abstract link to [email protected].

*All times are in PDT*

April 6

Opportunities for targeting RNA-protein interactions for cancer drug discovery

Amanda Garner, presenter
1:30 PM - 1:50 PM
Ballroom 6 CF - Upper Level

April 7

Designing the Next Generation of Antibody Drug Conjugates

Greg Thurber, chair and presenter
1:00 PM - 2:30 PM
Room 30 - Upper Level

Targeting Epigenetic Regulators of Oncogenic Transcription Factors

Arul M. Chinnaiyan, presenter
1:30 PM - 1:50 PM
Ballroom 6B - Upper Level

Identification of novel therapeutic vulnerabilities in inflammatory breast cancer

Nathan M. Merrill, presenter
1:55 PM - 2:15 PM
Room 16 - Mezzanine Level

Cancer Vaccines: Ready for Prime Time?

Ulka N. Vaishampayan, co-chair
3:00 PM - 5:00 PM
Ballroom 20 AB - Upper Level

MTX-531, a first-in-class pan-PI3K inhibitor spares hyperinsulinemia yielding durable tumor regressions and resilience to adaptive resistance

Judith Sebolt-Leopold, presenter
3:35 PM - 3:50 PM
Room 11 - Upper Level

Poster Session 1:30 PM - 5:00 PM

Pan-tissue master regulator inference reveals mechanisms of MHC alterations in cancers

Mahnoor Gondal
Section 36

Identification of isoform switching events linked with esophageal adenocarcinoma patient survival informs novel prognostic and therapeutic targets

Yang Zhang
Section 23

Targeting aurora kinase B (AURKB) as a radiosensitizing strategy in syngeneic models of triple negative breast cancer (TNBC)

Kassidy Jungles
Section 28

Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma can induce cellular apoptosis

Ananya Banerjee
Section 15

Malic enzyme 2 inhibition reveals metabolic vulnerability in serine-dependent triple-negative breast cancer

Mark Slayton
Section 18

Michigan cancer and research on the environment study (MI-CARES) cohort: Baseline methods and participant characteristics

Lilah Khoja
Section 34

Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC

Nathan M. Merrill
Section 9

April 8

Maria Castro, presenter
1:25 PM - 1:45 PM
Room 15 - Mezzanine Level

Development of potent, highly selective and efficacious SMARCA2 degraders

Lynda Yang, presenter
2:35 PM - 2:50 PM
Room 11 - Upper Level


Claudia Lalancette, presenter
3:00 PM - 4:00 PM
Spotlight Theater E - Sails Pavilion

Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression

Haibin Zhou, presenter
3:05 PM - 3:20 PM
Room 11 - Upper Level

Isolation and molecular characterization of exosomes from glioblastoma patients using a microfluidic device after ultrasound-based opening of the blood-brain barrier

Abha Kumari, presenter
3:35 PM - 3:50 PM
Room 6 B - Upper Level

Metabolic inhibition of BATF2 dampens type-I interferon-mediated immune sensing of cancer

Wang Gong, presenter
4:05 PM - 4:20 PM
Room 28 - Upper Level

What is a body weight “set point” and how can we change it?

Randy Seeley, presenter
5:10 PM - 5:30 PM
Room 30 - Upper Level

Poster Session 9:00 AM - 12:30 PM

HPV integration identifies emerging oncogenes and carcinogenic mechanisms, potentially indicating tumor recurrences

Shiting Li
Section 35

Anti-CADM1 chimeric antigen receptor (CAR) is a novel therapeutic strategy against small cell lung cancer

Shiva Katkam
Section 38

Circulating monocytes decrease significantly following disease-directed therapy and may reflect disease expansion in Langerhans cell histiocytosis

Haadi Ali
Section 45

Novel workflow to generate natural killer cell sensitivity prediction model based on the epithelial mesenchymal transition related reprogramming at a single cell resolution

Yin Zou
Section 46

Targeting lipid metabolism in pancreatic cancer

Christie Cheng
Section 29

Machine learning-based method to analyze metabolic fluxes of patient tumors

Baharan Meghdadi
Section 18

Rewiring of cortical glucose metabolism fuels human brain cancer growth

Anthony J. Scott
Section 18

Intrauterine device use and risk of invasive epithelial ovarian cancer: A population-based case-control study

Minh Phung
Section 33

FOXA1 alterations distinctively drive prostate tumorigenesis or therapy resistance in mice

Sanjana Eyunni
Section 6

Poster Session 1:30 PM - 5:00 PM

Tumor subtype classification of HPV-associated head and neck cancers is central to key clinically relevant variables

Bailey Garb
Section 34

Combined MEK and JAK inhibition in vitro is an effective strategy in overcoming JAK inhibitor resistance in primary myelofibrosis (PMF)

Samuel Reynolds
Section 40

Mutational analysis and spatial phenotyping to decipher racial disparities in pancreatic adenocarcinoma

Daniel Salas-Escabillas
Section 40

Enhancing STING activation by cyclic dinucleotide-manganese particles for systemic cancer immunotherapy

Xiang Zhou
Section 23

Targeting the GAS41 YEATS domain in non-small cell lung cancer with novel small molecules

Alyssa Winkler
Section 24

Harnessing PIKfyve as a therapeutic vulnerability in neuroendocrine prostate cancer

Yang Zheng
Section 27

Immunological targeting of integrin β1high/β3high melanoma

Feng Wang
Section 8

Development of the lipid kinase PIKfyve PROTAC degrader against neuroendocrine prostate cancer

Yuanyuan Qiao
Section 13

April 9

Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies

Lanbo Xiao, presenter
3:20 PM - 3:35 PM
Room 31 - Upper Level

KLIPP: Precision targeting of cancer with CRISPR

Mats Ljungman, presenter
3:50 PM - 4:05 PM
Ballroom 6A - Upper Level

Poster Session 9:00 AM - 12:30 PM

Discovery of CBPD-409 and CBPD-268 as highly potent and orally efficacious CBP/p300 PROTAC degraders for the treatment of castration-resistant prostate cancer

Zhixiang Chen
Section 21

Discovery of potent, highly selective and orally efficacious SMARCA2 degraders

L. Leng
Section 21

Discovery of potent and highly efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression

Ranjan Acharyya
Section 21

Orally bioavailable PROTAC based MDM2 degrader

Angelo Anguilar
Section 21

Discovery of an oral tricyclic STING agonist with superior pharmacokinetic properties and potent in vivo efficacy

Hongyi Zhao
Section 20

Genome instability in renal tumors

Hanbyul Cho
Section 46

Development of an ovarian cancer diagnosis score using electronic health records

Minh Phung
Section 38

Discovering novel ALK-lung carcinoma therapeutic strategies by identifying combinations with Alectinib from ALK-positive lung carcinoma cell lines

Hamadi Madhi
Section 23

Small molecule modulation of PP2A selectively induces oncogenic cytotoxicity through chronic and irreversible integrated stress response

Rita Avelar
Section 29

Immune inhibition of murine colorectal cancer by a p53 peptide mucosal vaccine

Shaomeng Wang

Section 5

Deletion of the lipid kinase PIKfyve in Kras-driven pancreatic genetically engineered mouse model

S. N. Yee
Section 14

The epigenetic factor BMI1 regulates metabolism and tumorigenesis in human pancreatic cancer cells

Jamie Mills
Section 18

To weight or not to weight? Studying the effect of selection bias in three EHR-linked biobanks with applications to colorectal cancer

Max Salvatore
Section 34

Poster Session 1:30 PM - 5:00 PM

Multimodality dietary intervention for colorectal cancer prevention: The MyBestGI randomized trial

Zora Djuric
Section 54

Development of prostate specific membrane antigen-targeted liposomal zinc for the treatment of prostate cancer

Sujan Mondal
Section 20

A novel CAR-NK cell therapy to target lung adenocarcinoma cells

Sergei Chuikov
Section 41

Overcoming B regulatory cell induced STING resistance by dual functional albumin nanomedicine to prolong survival of pancreatic cancer

Chengyi Li
Section 47

Targeting AR positive prostate cancer cells by the novel P300/CBP oral available PROTAC degrader

Jie Luo
Section 30

Efferocytosis-induced HIF-1α enhances tumor vascularization and promotes osteoblastic bone remodeling in metastatic prostate cancer

G.G. Kleer
Section 11

April 10

NG09 - NSD2 is a druggable subunit of the AR neo-enhanceosome in prostate cancer

Abhijit Parolia, presenter
10:45 AM - 11:05 AM
Room 15 - Mezzanine Level

Poster Session 9:00 AM - 12:30 PM

Proteogenomic and metabolomic characterization of acute myeloid leukemia

Yi Hsiao
Section 33

Priority targets in pancreatic cancer

Zeribe Nwosu
Section 33

Significance of the tryptophan catabolism pathway in triple-negative breast cancer shows potential targets in certain subsets relating to the serine pathway

Jin Jeon
Section 20

Longitudinal multi-omics characterization of circulating tumor cells from ALK positive NSCLC patients

Yuru Chen
Section 41

A systemically administered non-nucleotide STING agonist in albumin nanoformulation with potent antitumor activity and low toxicity

Jinsong Tao
Section 4

Chemoprevention of colorectal cancer: Role of trace minerals in conjunction with calcium

Muhammad Aslam
Section 30

Mutation specific mechanisms of resistance to oncogenic KRAS inhibition

Ivana Arravecchia
Section 8

Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy

Parth Borker
Section 40

p38-mediated EZH2 phosphorylation at T367 regulates HER2 pathway in triple negative breast cancer

Maria Gonzalez
Section 14